On November 10, 2026, BioNTech SE agreed to acquire a US FDA Priority Review Voucher from Scholar Rock, Inc. for $205 million, intending to use it for a future late-stage oncology filing; closing requires customary conditions, including HSR clearance.
BNTX · BioNTech SE
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
BioNTech said Gotistobard achieved median overall survival of 18.5 months versus 10 months with docetaxel in a global phase 3 lung-cancer trial, reducing death risk by 44%; the first pivotal interim analysis is expected before year end.
BioNTech SE reported revenue of 1,289.2 million euros for the three months ended September 30, 2026 and net profit of 184.5 million euros, while nine-month revenue was 1,512.9 million euros and net loss was 1,168.2 million euros.
BioNTech SE reported third-quarter revenue of €1,289.2 million and net profit of €184.5 million, raised full-year revenue guidance to €1,700 – €1,900 million, and reported €16.2 billion in cash, cash equivalents and security investments.
BioNTech SE and Bristol Myers Squibb Company reported first Phase 2 ROSETTA Lung-107 data: pumitamig plus docetaxel achieved a 36.7% confirmed objective response rate and 6.9-month median progression-free survival.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BNTX
this stock
BioNTech SE
|
$21.22B | -10.1% | — | — | 0.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$87.65B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 36
On November 10, 2026, BioNTech SE agreed to acquire a US FDA Priority Review Voucher from Scholar Rock, Inc. for $205 million, intending to use it for a future late-stage oncology filing; closing requires customary conditions, including HSR clearance.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BNTX | -2.2% | -2.4% | -7.2% | -2.9% | -10.1% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -4.8% | -1.3% | -7.7% | -2.7% | -20.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.